Updated Jul 16, 2026
Boulding Mark Elliott has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $13.55M.
Mark Elliott Boulding is the Executive Vice President and Chief Legal Officer at PTC Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare disorders. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 745 | $86.38 | $64K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 645 | $85.84 | $55K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.0K | $84.41 | $87K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 387 | $83.10 | $32K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 2.8K | $46.54 | $131K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 601 | $86.38 | $52K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 519 | $85.84 | $45K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 833 | $84.41 | $70K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 313 | $83.10 | $26K |
| 2026-07-08 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 2.3K | $39.42 | $89K |
| 2026-06-22 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 309 | $79.25 | $24K |
| 2026-06-22 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.7K | $78.50 | $134K |
| 2026-06-22 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 2.0K | $46.54 | $94K |
| 2026-06-22 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.9K | $79.24 | $147K |
| 2026-06-22 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 6.6K | $78.50 | $518K |
| 2026-06-22 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 8.5K | $46.54 | $396K |
| 2026-05-19 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 456 | $72.67 | $33K |
| 2026-05-19 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.4K | $72.08 | $170K |
| 2026-05-19 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 2.8K | $25.69 | $72K |
| 2026-05-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 600 | $79.28 | $48K |
Mark Elliott Boulding is the Executive Vice President and Chief Legal Officer at PTC Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare disorders. He has been involved in multiple SEC filings related to his role at the company.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 72 open-market sales ($13.55M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Boulding Mark Elliott profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.